¼¼°èÀÇ ÄÌ·ÎÀ̵å Ä¡·á ½ÃÀå
Keloid Treatment
»óǰÄÚµå : 1747820
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 280 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,130,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,390,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÄÌ·ÎÀ̵å Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 41¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 36¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÄÌ·ÎÀ̵å Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 2.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 41¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Æó¼â¼º µå·¹½ÌÀº CAGR 2.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 19¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Ð¹Ú ¿ä¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 1.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9¾ï 8,060¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÄÌ·ÎÀ̵å Ä¡·á ½ÃÀåÀº 2024³â¿¡ 9¾ï 8,060¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 7¾ï 6,750¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 4.1%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 0.9%¿Í 1.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.3%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÄÌ·ÎÀ̵å Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÄÌ·ÎÀ̵å Ä¡·á°¡ ÇǺΰú ¹× ¹Ì¿ë ÀÇ·á¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÄÌ·ÎÀ̵å´Â ÇǺΠ¼Õ»ó ºÎÀ§¿¡ ¹ß»ýÇÏ´Â ºñÁ¤»óÀûÀÎ ¼¶À¯¼º °úÇü¼ºÀ̸ç, Á¾Á¾ ¿ø·¡ÀÇ »óó °¡ÀåÀÚ¸®¸¦ ³Ñ¾î¼­¼­ óÀ½ ¿Ü»óÀÌ Ä¡À¯µÈ ÈÄ¿¡µµ ¿À·§µ¿¾È Áö¼ÓµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÄÌ·ÎÀ̵å´Â ¾ç¼ºÀÌÁö¸¸, ºÎÇ®¾î ¿À¸£°í, º¯»öµÇ°í, ¶§·Î´Â ÅëÁõÀ» µ¿¹ÝÇϱ⠶§¹®¿¡ ½ÅüÀûÀ¸·Î ºÒÆíÇÏ°í ½É¸®ÀûÀ¸·Î °íÅ뽺·¯¿ï ¼ö ÀÖ½À´Ï´Ù. ÄÌ·ÎÀ̵忡 ´ëÇÑ Ä¡·á ¹× ¹Ì¿ë ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ƯÈ÷ ÇǺΠ°Ç°­ ¹× ¹Ì¿ë ÇǺΰú¿¡ ´ëÇÑ ÀνÄÀÌ ´Ù¾çÇÑ »ç¶÷µé »çÀÌ¿¡¼­ È®´ëµÊ¿¡ µû¶ó ¼¼°è Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ º´º¯Àº ƯÈ÷ ¾ÆÇÁ¸®Ä«°è, ¾Æ½Ã¾Æ°è, ¶óƾ¾Æ¸Þ¸®Ä«°è µî ¾îµÎ¿î ÇǺλöÀ» °¡Áø »ç¶÷µé¿¡°Ô ºÒ±ÕÇüÀûÀ¸·Î ¿µÇâÀ» ¹ÌÄ¡¸ç, À¯ÀüÀû ¼ÒÀÎÀÌ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ¹ÎÁ· ÇǺΰúÇÐÀ» º¸´Ù Àû±ØÀûÀ¸·Î µµÀÔÇÔ¿¡ µû¶ó, ±Ù°Å¿¡ ±â¹ÝÇÑ Ç¥ÀûÈ­µÈ ÄÌ·ÎÀ̵å Ä¡·áÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÄÌ·ÎÀ̵å´Â Àç¹ß·üÀÌ ³ô°í Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀµµ ´Ù¾çÇϱ⠶§¹®¿¡ ÄÌ·ÎÀ̵åÀÇ °ü¸®¿¡´Â ÀϹÝÀûÀ¸·Î ´Ù°¢ÀûÀÎ Á¢±ÙÀÌ ÇÊ¿äÇÕ´Ï´Ù. µû¶ó¼­ È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÌ¸ç ¿À·¡ Áö¼ÓµÇ´Â Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä´Â ÇǺΰú Áø·á¿¡¼­ ÀÓ»ó ¿¬±¸¿Í ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÄÌ·ÎÀ̵å Ä¡·áÀÇ ÁÖ¿ä Ä¡·á¹ý°ú ±× ¹ßÀüÀº?

ÄÌ·ÎÀ̵å Ä¡·á¿¡´Â ÀüÅëÀûÀÎ Ä¡·á¹ýºÎÅÍ »õ·Î¿î ±â¼ú±îÁö ´Ù¾çÇÑ Á¢±Ù¹ýÀÌ ÀÖ½À´Ï´Ù. 1Â÷ÀûÀÎ Ä¡·á¹ýÀ¸·Î´Â ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å Áֻ簡 ÈçÈ÷ ½ÃÇàµÇ¸ç, ¿°Áõ°ú Äݶó°Õ ÇÕ¼ºÀ» ¾ïÁ¦ÇÏ°í ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ÈäÅ͸¦ ÆòÆòÇÏ°Ô ÇÏ°í ºÎµå·´°Ô ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, 5-Ç÷ç¿À·Î¿ì¶ó½Ç(5-FU)À̳ª ºí·¹¿À¸¶À̽Űú ÇÔ²² »ç¿ëÇÏ¸é ´õ ³ôÀº È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ³Ãµ¿¿ä¹ýÀº ¾×ü Áú¼Ò¸¦ ÀÌ¿ëÇÏ¿© ÄÌ·ÎÀ̵å Á¶Á÷À» µ¿°á½ÃÄÑ ºÎÇǸ¦ °¨¼Ò½ÃŰ´Â °ÍÀ¸·Î, º´º¯ÀÌ ÀÛÀº °æ¿ì³ª ³»½Ã°æ Ä¡·á¿Í º´ÇàÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

·¹ÀÌÀú Ä¡·á, ƯÈ÷ ÆÞ½º »ö¼Ò ·¹ÀÌÀú(PDL)¿Í ÇÁ¶ô¼Å³Î CO2 ·¹ÀÌÀú´Â Äݶó°Õ ¸®¸ðµ¨¸µÀ» ÀÚ±ØÇϸ鼭 ÄÌ·ÎÀ̵åÀÇ Áú°¨, »ö, ºÒÆí°¨À» °³¼±ÇÏ´Â Ä¡·á¹ýÀ¸·Î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¼ö¼úÀû ÀýÁ¦°¡ ÇÊ¿äÇÑ °æ¿ìµµ ÀÖÁö¸¸ ¹æ»ç¼± Ä¡·á, ¾Ð¹Ú¿ä¹ý, ½Ç¸®ÄÜ°Ö ½ÃÆ® µîÀÇ º¸Á¶¿ä¹ýÀ» º´ÇàÇÏÁö ¾ÊÀ¸¸é Àç¹ß À§ÇèÀÌ ³ô½À´Ï´Ù. ÃÖ±Ù Ãß¼¼·Î´Â »óó ºÎÀ§ÀÇ ±â°èÀû ±äÀåÀ» ¿ÏÈ­Çϱâ À§ÇÑ º¸Åø¸®´®Åö½Å(º¸Å彺) ÁÖ»çÀÇ »ç¿ë°ú ¼¶À¯Áõ½Ä °úÁ¤ÀÇ ±Ùº»ÀûÀÎ ¿øÀÎÀ» ÇØ°áÇϱâ À§ÇÑ Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¿Í À¯ÀüÀÚ º¯Çü Ä¡·áÀÇ Àû¿ëÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Áõ»ó ¾ïÁ¦¿¡ ±×Ä¡Áö ¾Ê°í Àå±âÀûÀÎ °ü¸® ¹× ¿¹¹æÀ¸·Î ÄÌ·ÎÀ̵å Ä¡·á¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù.

ÄÌ·ÎÀ̵å Ä¡·á ½ÃÀå ¼ö¿ä¸¦ ÁÖµµÇϴ ȯÀÚ±º°ú ÀÓ»ó ÇöÀåÀº?

ÄÌ·ÎÀ̵å Ä¡·á¸¦ ã´Â ȯÀÚµéÀº °¡·Á¿òÁõ, ÀÛ¿­°¨, ¿îµ¿ Á¦ÇѰú °°Àº ½ÅüÀû Áõ»ó°ú ½É¸®Àû °íÅë, ¹Ì¿ëÀû °ü½É µî ÀÇ·á¿Í ¹Ì¿ëÀÇ µÎ ¿µ¿ª¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. ÀþÀº ¿¬·ÉÃþ, ƯÈ÷ 20-40´ë ȯÀÚµéÀº ¹Ì¿ë ½Ã¼ú°ú ÆÛ½º³ÎÄɾ ´ëÇÑ °ü½ÉÀÌ ³ô±â ¶§¹®¿¡ ¼ö¿äÀÇ ÁÖ¿ä °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÇǾî½Ì, È­»ó, ¿©µå¸§ ȸº¹À» Æ÷ÇÔÇÑ ¼ö¼ú ÈÄ ¹× ¿Ü»ó ÈÄ È¯ÀÚµéÀº ¶Ç ´Ù¸¥ Áß¿äÇÑ »ç¿ëÀÚÃþÀÔ´Ï´Ù.

ÇǺΰú ÀÇ»ç, ¼ºÇü¿Ü°ú ÀÇ»ç, Á¾¾ç¿Ü°ú ÀÇ»ç, ¹Ì¿ë ÀÇ·á Á¾»çÀÚµéÀº ÄÌ·ÎÀÌµå °ü¸®¸¦ ÀÓ»ó¿¡ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÇǺΰú¿Í µðÁöÅÐ Áø·á Ç÷§ÆûÀÇ µîÀåÀº ƯÈ÷ Àü¹®ÀûÀÎ ÇǺΠġ·á°¡ Á¦ÇÑÀûÀ̾ú´ø ¼Ò¿ÜµÈ Áö¿ª¿¡¼­ Àü¹®°¡ÀÇ Ä¡·á¸¦ º¸´Ù ½±°Ô Á¢ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¸ÞµðÄà ½ºÆÄ, ¿Ü·¡ Áø·á¼Ò, ¹Ì¿ë ¼ö¼ú¼¾Å͵µ ·¹ÀÌÀú Ä¡·á¿Í ÁÖ»çÁ¦¸¦ °áÇÕÇÑ ÃÖ¼Ò Ä§½ÀÀû Ä¡·á ÆÐŰÁö¸¦ Á¦°øÇÏ¿© Á¾ÇÕÀûÀÎ °á°ú¸¦ ¾òÀ½À¸·Î½á ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºñ¼ö¼úÀûÀÌ°í ´Ù¿îŸÀÓÀÌ ÀûÀº Ä¡·á¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ¼±È£µµ º¯È­´Â Àü ¼¼°èÀûÀ¸·Î ÄÌ·ÎÀ̵å Ä¡·áÀÇ Á¦°ø ¸ðµ¨À» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

ÄÌ·ÎÀ̵å Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

ÄÌ·ÎÀ̵å Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ºñÈļº ÈäÅÍ ÁúȯÀÇ À¯º´·ü Áõ°¡, ÇǺΠ°Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¹Ì¿ë ÇǺΰú ±â¼ú ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °í·ÉÈ­¿Í ¼ö¼ú ¹× ¹Ì¿ë ¼ºÇüÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¼ú ÈÄ ¶Ç´Â ¿Ü»ó °ü·Ã ÄÌ·ÎÀÌµå ¹ß»ý·üÀÌ Áõ°¡ÇÏ¿© È¿°úÀûÀÎ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ·¹ÀÌÀú ±â¹Ý Ç÷§Æû, »ý¹°ÇÐÀû Á¦Á¦ ¹× º´¿ë ¿ä¹ýÀÇ º¸±ÞÀº ÀÓ»ó °á°ú¿Í ȯÀÚ ¸¸Á·µµ¸¦ °³¼±ÇÏ¿© äÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÅÈï±¹À» Áß½ÉÀ¸·Î È®´ëµÇ°í ÀÖ´Â ¹Ì¿ë ÇǺΰú ºÐ¾ß´Â ÄÌ·ÎÀ̵忡 ƯȭµÈ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ±âÁ¸ ºê·£µå¿Í ½Å±Ô ÁøÃâ±â¾÷ ¸ðµÎ¿¡°Ô »õ·Î¿î ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î Á¦Á¦ÀÇ ±ÔÁ¦ ½ÂÀÎ, ¿Ü¿ëÁ¦ Àü´Þ ½Ã½ºÅÛ °­È­, AI ¹× ¿µ»ó µµ±¸¸¦ ÅëÇÑ °³Àκ° ¸ÂÃã Ä¡·á °èȹÀÇ ¿ªÇÒ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÄÌ·ÎÀ̵å Ä¡·á°¡ Á¾ÇÕÀûÀÎ ÈäÅÍ °ü¸® ¹× ¹Ì¿ë º¹¿ø ¼­ºñ½º¿¡ ÅëÇյǸ鼭 ÇコÄÉ¾î ¹× ¹Ì¿ë ºÐ¾ß Àü¹Ý¿¡ °ÉÃÄ ÄÌ·ÎÀ̵å Ä¡·áÀÇ ¸Å·ÂÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÇǺΠ»óÅ °³¼±¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÄÌ·ÎÀ̵å Ä¡·á ½ÃÀåÀº Áö¼ÓÀûÀÎ Çõ½Å°ú »ó¾÷Àû È®ÀåÀ» ±â´ëÇÒ ¼ö ÀÖ´Â À§Ä¡¿¡ ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·á(ºØ´ë ¿ä¹ý, ¾Ð¹Ú ¿ä¹ý, µ¿°á ¼ö¼ú, ÀýÁ¦¼ú, ±âŸ Ä¡·á), ÃÖÁ¾ ¿ëµµ(º´¿ø, ÇǺΰú Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÇÕ°è 34 ÁÖ¸ñ)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Keloid Treatment Market to Reach US$4.1 Billion by 2030

The global market for Keloid Treatment estimated at US$3.6 Billion in the year 2024, is expected to reach US$4.1 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Occlusive Dressing, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Compression Therapy segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$980.6 Million While China is Forecast to Grow at 4.1% CAGR

The Keloid Treatment market in the U.S. is estimated at US$980.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$767.5 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Keloid Treatment Market - Key Trends & Drivers Summarized

Why Is Keloid Treatment Becoming a Priority in Dermatological and Aesthetic Medicine?

Keloids are abnormal, fibrous overgrowths that occur at the site of skin injuries, often extending beyond the original wound margin and persisting long after the initial trauma has healed. While they are benign, keloids can be physically uncomfortable and psychologically distressing due to their raised, discolored, and sometimes painful nature. The increasing demand for both therapeutic and aesthetic solutions for keloids is propelling growth in the global treatment market, especially as awareness of skin health and cosmetic dermatology expands across diverse populations.

These lesions disproportionately affect individuals with darker skin types, particularly in populations of African, Asian, and Latin American descent, where genetic predisposition plays a significant role. As global health systems become more inclusive of ethnic dermatology, the need for targeted, evidence-based keloid treatments is rising. Keloid management typically requires a multimodal approach, as the condition has a high recurrence rate and variable response to therapy. The demand for effective, minimally invasive, and long-lasting treatments is therefore driving both clinical research and innovation in dermatological practices.

What Are the Leading Modalities in Keloid Management and How Are They Evolving?

The treatment of keloids involves a variety of approaches, ranging from conventional therapies to emerging technologies. First-line treatments often include corticosteroid injections, which reduce inflammation and collagen synthesis, helping to flatten and soften the scar over time. These may be combined with 5-fluorouracil (5-FU) or bleomycin to enhance efficacy. Cryotherapy, which uses liquid nitrogen to freeze and reduce the volume of keloid tissue, is frequently employed for smaller lesions or in conjunction with intralesional therapy.

Laser therapy-particularly pulsed dye lasers (PDL) and fractional CO2 lasers-is gaining popularity for improving keloid texture, color, and discomfort while stimulating collagen remodeling. Surgical excision, while sometimes necessary, carries a high risk of recurrence unless paired with adjunct therapies like radiation, pressure therapy, or silicone gel sheeting. More recent developments include the use of botulinum toxin injections to reduce mechanical tension at wound edges and the application of stem cell-based or gene-modifying treatments aimed at addressing the underlying fibroproliferative processes. These innovations are expanding the keloid treatment landscape beyond symptom suppression toward long-term management and prevention.

Which Patient Groups and Clinical Practices Are Driving Market Demand for Keloid Solutions?

Patients seeking keloid treatment span both medical and cosmetic domains, with individuals motivated by physical symptoms such as itching, burning, or restricted movement, as well as psychological distress and cosmetic concerns. Younger patients, particularly in the 20-40 age group, are key drivers of demand due to higher engagement with aesthetic procedures and personal care. Post-surgical and post-trauma patients, including those recovering from piercings, burns, and acne, represent another significant user base.

Dermatologists, plastic surgeons, oncologic surgeons, and aesthetic medicine practitioners are increasingly incorporating keloid management into their clinical offerings. The rise of teledermatology and digital consultation platforms is making expert care more accessible, especially in underserved regions where specialist skin care was previously limited. Medical spas, outpatient clinics, and cosmetic surgery centers are also contributing to market expansion by offering minimally invasive treatment packages, often combining laser therapy and injectables for comprehensive results. The shift in patient preference toward non-surgical, low-downtime interventions is shaping the delivery model of keloid care globally.

The Growth in the Keloid Treatment Market Is Driven by Several Factors…

The growth in the keloid treatment market is driven by several factors including the rising prevalence of hypertrophic scarring disorders, increasing awareness of skin health, and technological advancements in aesthetic dermatology. As populations age and undergo more surgeries and aesthetic procedures, the incidence of post-operative and trauma-related keloids is rising, fueling the need for effective treatment protocols. The proliferation of laser-based platforms, biologics, and combination therapies is also improving clinical outcomes and patient satisfaction, further encouraging adoption.

The expanding cosmetic dermatology sector-particularly in emerging economies-is creating new opportunities for both established brands and novel entrants offering keloid-specific solutions. Regulatory approvals of new drug formulations, enhanced delivery systems for topical agents, and the growing role of personalized treatment planning through AI and imaging tools are also contributing to market momentum. Furthermore, the integration of keloid treatment into comprehensive scar management and aesthetic restoration services is broadening its appeal across healthcare and beauty disciplines. As demand for skin condition correction continues to grow, the keloid treatment market is positioned for sustained innovation and commercial expansion.

SCOPE OF STUDY:

The report analyzes the Keloid Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Occlusive Dressing, Compression Therapy, Cryosurgery, Excision, Other Treatments); End-Use (Hospitals, Dermatology Clinics, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â